NicOx reports first quarter 2008 financial results SOPHIA ANTIPOLIS, FRANCE -- (MARKET WIRE) -- 05/14/08 -- May 14, 2008.Sophia Antipolis, France.
www.nicox.com NicOx S.A.
(Eurolist: COX) today reported financial results for the first three months of 2008.
On March 31, 2008, the...
NicOx reports first quarter 2008 financial results NicOx S.A.(Eurolist: COX) today reported financial results for the first three months of 2008.
On March 31, 2008, the Company had cash, cash equivalents and financial instruments of EUR 153.7 million, compared to EUR 201.2 million on...
NicOx reports first quarter 2008 financial results Sophia Antipolis, France.www.nicox.com NicOx S.A.
(Eurolist: COX) today reported financial results for the first three months of 2008.
On March 31, 2008, the Company had cash, cash equivalents and financial instruments of EUR 153.7...
NicOx Reports First Quarter 2008 Financial Results SOPHIA ANTIPOLIS, France, May 14 /PRNewswire-FirstCall/ -- NicOx S.A.(News) (Eurolist: COX) today reported financial results for the first three months of 2008.
On March 31, 2008, the Company had cash, cash equivalents and financial...
Viterra and BioExx Execute Long-Term Supply Agreement , 4:04 AM EST Viterra Inc.(TSX: VT) ('Viterra') and Bio-Extraction Inc.
(TSX VENTURE: BXI) ('BioExx') are pleased to announce that they have entered into a long-term Canola Supply Agreement under which Viterra will supply canola...
Adherex Announces Agreement for STS Phase III Data ET RESEARCH TRIANGLE PARK, NORTH CAROLINA--(MARKET WIRE)--May 14, 2008 -- Adherex Technologies Inc.(Toronto: - )(AMEX: - ), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today a license ...
ADH: License Agreement w/Netherlands Cancer Institute for Use of Ph III Data ADHEREX TECHNOLOGIES INC By Fain Hughes, fhughes@knobias.com Adherex Technologies Inc.(ADH) announced a license agreement with the Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital (NKI-AVL), for the exclusive use of...
Forest and Daiichi Sankyo end hypertensive pact Forest Laboratories, Inc.a U.S.-based pharmaceutical company, and Daiichi Sankyo, Inc.
have terminated their co-promotion agreement for Azor (amlodipine and olmesartan medoxomil), Daiichi Sankyo's fixed-dose combination of two...
Intas Biopharma to expand operations in Middle East, North Africa The Ahmedabad based, Intas Biopharmaceuticals Ltd is expanding its operations in Middle East and North Africa (MENA).The company is looking forward to supply and market three products, Neukine, Erykine and Intalfa in these markets.
The...
Settling it out Of late, pharmaceutical companies seem to be resorting to out-of-court settlements, in a bid to put an end to time consuming legal hassles and piling up bills.Suja Nair analyses recent out-of-court settlements There is fierce competition...
Warnex Reports First Quarter 2008 Results - First quarter revenue of $6.1 million and net loss of $0.3 million - Signed agreements in principle with Warnex's various debenture holders in order to modify the terms and conditions of the long term debentures - Signed 10-year...
Co-Development and Co-Marketing Agreement Secured for the Activated Vitamin D Derivative, ED-71 (Tokyo) - Chugai Pharmaceutical Co., Ltd.('Chugai') [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama] announced today that it has entered into an agreement with Taisho Pharmaceutical Co., Ltd.
('Taisho') [Head Office:...
Adherex Announces Agreement for STS Phase III Data - Adherex Technologies Inc.(TSX:AHX)(AMEX:ADH), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today a license agreement with the Netherlands Cancer Institute - Antoni van Leeuwenhoek...
GSK signs pact with Japanese firm Mumbai (PTI): Pharmaceutical firm GlaxoSmithKline (GSK) Pharma on Wednesday said it has entered into an agreement with Daiichi Sankyo India Pharma Limited (DSIPL) for jointly promoting the anti-hypertensive drug Olmesartan Medoxomil...
Forest and Daiichi terminate Azor co-promotion agreement Forest will record a one-time charge of $44.1 million which is composed of a one-time payment to Daiichi Sankyo of $26.6 million related to the termination and $17.5 million related to the unamortized portion of the initial upfront payment....
Indevus Pharmaceuticals Inc. F2Q08 (Qtr End 3/31/08) Earnings Call Transcript Good day ladies and gentlemen and welcome to the 2008 second quarter Indevus Pharmaceuticals Incorporated Earnings Call.My name is Cynthia, and Ill be your Operator for todays call.
At this time, all participants are in a listen-only...
Crucell Announces First Quarter 2008 Results Total revenue and other operating income of EUR 47.9 million, showing 36% growth in the first quarter of 2008 compared to EUR 35.2 million in the same period of 2007.Net loss in the quarter halved to EUR 9.0 million compared to Q107.
Full Article Avoid Misunderstanding by Making Sure Your Agreement Is Clear and Accurate Larry A.Roberts So, youve got a patent but you dont have the resources to market the patented invention.
Or you have the manufacturing and marketing...
Ranbaxy & Merck Sign Strategic Product Development Agreement in anti-infective field Ranbaxy Laboratories Ltd has announced today that they have signed a strategic Product Development Agreement (the 'Agreement') providing for a drug discovery and clinical development collaboration for new products, in the anti...
EP MedSystems Reports 2008 First Quarter Results , 4:37 PM EST News source: Business Wire EP MedSystems, Inc.(NASDAQ: EPMD), today reported its financial results for the first quarter ending March 31, 2008.
The Company achieved quarterly revenue of $4.6 million, representing a 29%...
Quest PharmaTech Signs Agreement to sell Bionex Technology uest PharmaTech Inc.announced that it has signed a Technology Transfer Agreement with Peking Marvel Cleansing Supplies Co., Ltd., a China-based company, to sell its interest in the Bionex Technology.
Peking Marvel is anticipated...
Forest Laboratories and Daiichi Sankyo Terminate AZOR Copromotion Agreement Forest Laboratoriesand Daiichi Sankyo terminated their copromotion agreement for AZOR (amlodipine and olmesartan medoxomil), Daiichi Sankyo's fixed-dose combination of two antihypertensives, the calcium channel blocker amlodipine...
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement NEW YORK and PARSIPPANY, N.J., May 12 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc., a U.S.-based pharmaceutical company, and Daiichi Sankyo, Inc.
today announced that they have terminated their co-promotion agreement for...
Skinvisible Signs Licensing Agreement For Two Acne Formulations New Retinoic Acid and Clindamycin Products Developed with Invisicare LAS VEGAS, Nevada - May 13, 2008 - Skinvisible, Inc.(OTC Bulletin Board: SKVI / http://www.skinvisible.com), a research and development company focused on formulating...
Examine The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profi The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profiles http://www.reportlinker.com/p088534/The-Fastest-Growing-Biotechnology-Companies- Growth-strategies-comparative-analyses-and-company...
